Established clinical use of octreotide and lanreotide in oncology

Chemotherapy

Volumn 47, Issue SUPPL. 2, 2001, Pages 40-53

  Oberg K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Lanreotide; Neuroendocrine tumors; Octastatin; Octreoscan; Octreotide

Indexed keywords

ANGIOPEPTIN; INDIUM 111; LONG ACTING DRUG; OCTREOTIDE; PENTETREOTIDE; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; DRUG FORMULATION; HUMAN; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 0035082591     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049160     Document Type: Review

References (65)

1. Neuroendocrine tumors
2. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production and survival
3. Carcinoid tumors and syndrome
4. Neuroendocrine pancreatic tumors: Clinical presentation, biochemical and histopathological findings in 84 patients
5. The gastroenteropancreatic endocrine system and related tumors
6. Zollinger-Ellison syndrome: Current concepts and management
7. Insulin-producing islet cell tumors
8. Clinicopathological study of pancreatic and ganglioneuroblastoma tumors secreting vasoactive intestinal polypeptide (VIPomas)
9. The glucagonoma syndrome; clinical features, diagnosis and treatment
10. Multiple endocrine neoplasia type 1: A ten year prospective screening study in four kindreds
11. Surgical treatment of midgut carcinoid tumors
12. Apudoma metastatic to the liver: Treatment by hepatic artery embolization
13. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors
14. 125I-MIBG in the diagnosis and therapy of carcinoids
15. Yttrium-90-labelled somatostatin analoague for cancer treatment
16. The management of patients with advanced carcinoid tumours and islet cell carcinomas
17. An update of the medical treatment of malignant endocrine pancreatic tumors
18. Cytotoxic treatment in patients with malignant carcinoid tumours; response to streptozocin - Alone or in combination with 5-FU
19. Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results
20. The role of interferons in the management of carcinoid tumors
21. Cloning and functional characterization of a family of human and mouse somatostatin receptors expresssed in brain, gastrointestinal tract and kidney
22. Somatostatin receptor subtypes, SSTR-1, SSTR-2, SSTR-3 and SSTR-5 expression in human pituitary, gastroenteropancreatic and mammary tumors: Comparison of mRNA analysis with receptor autoradiography
23. Somatostatin receptors
24. Determination of somatostatin receptor subtype 2 in carcinoid tumours by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies
25. Immunohistochemical localization of somatostatin receptors, SSTR-2A in human tumors
26. Somatostatin analogue: An inhibitor of angiogenesis?
27. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
28. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
29. Potentiation of the anti-proliferative effects of anticancer drugs by octreotide in vitro and in vivo
30. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumour-host interaction?
31. 3)-octreotide. The Rotterdam experience with more than 1,000 patients
32. 1)-Octreotide scintigraphy in patients with carcinoid tumors: The predictive value for somatostatin analog treatment
33. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management
34. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumours
35. 1)-Octreotide scintigraphy in patients with carcinoid tumors; the predictive value for somatostatin analogue treatment
36. Octreotide
37. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue
38. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
39. Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analogue
40. Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumors
41. Somatostatin analogues in the management of endocrine tumors of the pancreas
42. Long-term treatment with octreotide in patients with Zollinger-Ellison syndrome
43. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth
44. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
45. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: Symptomatic and peptide response
46. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 2011-995)
47. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing post-translational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth
48. Use of somatostatin analogue octreotide to localize and manage somatostatin-producing tumors
49. Octreotide treatment of carcinoid syndrome: Analysis of published dose-titration data
50. Octreotide as an anti-neoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
51. Somatostatin analogue and inhibition of tumor growth in metastatic endocrine gastroentero-pancreatic tumors
52. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group
53. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours; clinical and biological effects
54. Somatostatin analogue phase I trials in neuroendocrine neoplasms
55. Dose-dependent and antiproliferative effects of somatostatin
56. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours
57. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
58. Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly
59. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells
60. Sandostatin-LAR: Pharmaco-kinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients
61. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients
62. Efficacy and safety of lanreotide prolonged release in patients with gastrointestinal neuroendocrine tumors with hormone related symptoms
63. Octreotide and interferon alpha: A new combination for the treatment of malignant carcinoid tumours
64. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumours
65. Somatostatin receptor (SSTR) subtype-selective analogs differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumours